Literature DB >> 23649883

Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics.

J Martínez-Clemente1, R López-Arnau, M Carbó, D Pubill, J Camarasa, E Escubedo.   

Abstract

RATIONALE: Mephedrone (4-methylmethcathinone) is a still poorly known drug of abuse, alternative to ecstasy or cocaine.
OBJECTIVE: The major aims were to investigate the pharmacokinetics and locomotor activity of mephedrone in rats and provide a pharmacokinetic/pharmacodynamic model.
METHODS: Mephedrone was administered to male Sprague-Dawley rats intravenously (10 mg/kg) and orally (30 and 60 mg/kg). Plasma concentrations and metabolites were characterized using LC/MS and LC-MS/MS fragmentation patterns. Locomotor activity was monitored for 180-240 min.
RESULTS: Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α = 10.23 h(-1), β = 1.86 h(-1)). After oral administration, peak mephedrone concentrations were achieved between 0.5 and 1 h and declined to undetectable levels at 9 h. The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%. We have identified five phase I metabolites in rat blood after oral administration. The relationship between brain levels and free plasma concentration was 1.85 ± 0.08. Mephedrone induced a dose-dependent increase in locomotor activity, which lasted up to 2 h. The pharmacokinetic-pharmacodynamic model successfully describes the relationship between mephedrone plasma concentrations and its psychostimulant effect.
CONCLUSIONS: We suggest a very important first-pass effect for mephedrone after oral administration and an easy access to the central nervous system. The model described might be useful in the estimation and prediction of the onset, magnitude, and time course of mephedrone pharmacodynamics as well as to design new animal models of mephedrone addiction and toxicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23649883     DOI: 10.1007/s00213-013-3108-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

Review 1.  Structure-brain exposure relationships.

Authors:  Stephen A Hitchcock; Lewis D Pennington
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

2.  4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Authors:  Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-08-02       Impact factor: 4.030

3.  Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry.

Authors:  Lambert K Sørensen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-02-13       Impact factor: 3.205

4.  Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats.

Authors:  Kurt J Varner; Kyle Daigle; Peter F Weed; Peter B Lewis; Sarah E Mahne; Ananthakrishnan Sankaranarayanan; Peter J Winsauer
Journal:  Psychopharmacology (Berl)       Date:  2012-09-13       Impact factor: 4.530

5.  Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone.

Authors:  Raul López-Arnau; Jose Martínez-Clemente; David Pubill; Elena Escubedo; Jorge Camarasa
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

6.  Interaction of mephedrone with dopamine and serotonin targets in rats.

Authors:  José Martínez-Clemente; Elena Escubedo; David Pubill; Jorge Camarasa
Journal:  Eur Neuropsychopharmacol       Date:  2011-08-06       Impact factor: 4.600

7.  Pharmacological characterization of designer cathinones in vitro.

Authors:  L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

8.  Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines.

Authors:  N V Cozzi; M K Sievert; A T Shulgin; P Jacob; A E Ruoho
Journal:  Eur J Pharmacol       Date:  1999-09-17       Impact factor: 4.432

9.  Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics.

Authors:  H C Porchet; N L Benowitz; L B Sheiner; J R Copeland
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

10.  Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).

Authors:  Julien Fonsart; Marie-Claude Menet; Marcel Debray; Déborah Hirt; Florence Noble; Jean-Michel Scherrmann; Xavier Declèves
Journal:  Toxicol Appl Pharmacol       Date:  2009-09-23       Impact factor: 4.219

View more
  20 in total

Review 1.  The preclinical pharmacology of mephedrone; not just MDMA by another name.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 2.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

3.  Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats.

Authors:  Ryan A Gregg; Michael H Baumann; John S Partilla; Julie S Bonano; Alexandre Vouga; Christopher S Tallarida; Venkata Velvadapu; Garry R Smith; M Melissa Peet; Allen B Reitz; S Stevens Negus; Scott M Rawls
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

4.  Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS.

Authors:  Eulàlia Olesti; Magí Farré; Esther Papaseit; Aristotelis Krotonoulas; Mitona Pujadas; Rafael de la Torre; Óscar J Pozo
Journal:  AAPS J       Date:  2017-08-21       Impact factor: 4.009

5.  Synthetic cathinones and stereochemistry: S enantiomer of mephedrone reduces anxiety- and depressant-like effects in cocaine- or MDPV-abstinent rats.

Authors:  Helene L Philogene-Khalid; Callum Hicks; Allen B Reitz; Lee-Yuan Liu-Chen; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2017-06-13       Impact factor: 4.492

6.  Human Pharmacology of Mephedrone in Comparison with MDMA.

Authors:  Esther Papaseit; Clara Pérez-Mañá; Julián-Andrés Mateus; Mitona Pujadas; Francina Fonseca; Marta Torrens; Eulàlia Olesti; Rafael de la Torre; Magí Farré
Journal:  Neuropsychopharmacology       Date:  2016-05-20       Impact factor: 7.853

7.  Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats.

Authors:  Blake A Hutsell; Michael H Baumann; John S Partilla; Matthew L Banks; Rakesh Vekariya; Richard A Glennon; S Stevens Negus
Journal:  Eur Neuropsychopharmacol       Date:  2015-12-11       Impact factor: 4.600

8.  Effect of the combination of mephedrone plus ethanol on serotonin and dopamine release in the nucleus accumbens and medial prefrontal cortex of awake rats.

Authors:  Raúl López-Arnau; Mario Buenrostro-Jáuregui; Jorge Camarasa; David Pubill; Elena Escubedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-01-18       Impact factor: 3.000

9.  The clinical challenges of synthetic cathinones.

Authors:  Fabrizio Schifano; Flavia Napoletano; Davide Arillotta; Caroline Zangani; Liam Gilgar; Amira Guirguis; John Martin Corkery; Alessandro Vento
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

Review 10.  An updated review on synthetic cathinones.

Authors:  Jorge Soares; Vera Marisa Costa; Maria de Lourdes Bastos; Félix Carvalho; João Paulo Capela
Journal:  Arch Toxicol       Date:  2021-06-08       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.